Bavarian Nordic A/S (BVNRY)

OTCMKTS: BVNRY · Delayed Price · USD
7.03
-0.11 (-1.49%)
Apr 17, 2024, 1:24 PM EDT - Market open
Market Cap 1.64B
Revenue (ttm) 1.01B
Net Income (ttm) 210.47M
Shares Out 233.75M
EPS (ttm) 2.73
PE Ratio 2.58
Forward PE 0.60
Dividend n/a
Ex-Dividend Date n/a
Volume 2,193
Open 7.02
Previous Close 7.14
Day's Range 7.02 - 7.03
52-Week Range 5.95 - 10.65
Beta 1.33
Analysts n/a
Price Target n/a
Earnings Date n/a

About BVNRY

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phas... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1992
Employees 1,379
Stock Exchange OTCMKTS
Ticker Symbol BVNRY
Full Company Profile

Financial Performance

Financial numbers in DKK Financial Statements

News

Morris & Dickson is the First U.S. Distributor for Bavarian Nordic's JYNNEOS®, the Only FDA-approved Mpox Vaccine

SHREVEPORT, La.--(BUSINESS WIRE)--Morris & Dickson is proud to announce it is the first U.S. distributor of Bavarian Nordic's newly launched mpox vaccine, JYNNEOS®. As the only FDA-approved mpox vacci...

14 days ago - Business Wire

Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.

COPENHAGEN, Denmark, April 2, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that JYNNEOS®, the only FDA-approved mpox vaccine, is now commercially available in the U.S., marking a significant...

15 days ago - GlobeNewsWire

Bavarian Nordic A/S – Notice Convening Annual General Meeting

COPENHAGEN, Denmark, March 21, 2024 – Pursuant to Articles 10-14 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the Annual General Meeting to be held on

27 days ago - GlobeNewsWire

Bavarian Nordic Receives Approval of Smallpox and Mpox Vaccine in Switzerland

COPENHAGEN, Denmark, March 13, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Swiss Agency for Therapeutic Products, Swissmedic, has approved JYNNEOS® (MVA-BN) for active immunization...

5 weeks ago - GlobeNewsWire

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

COPENHAGEN, Denmark, March 12, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company's shares/related securities by persons holding mana...

5 weeks ago - GlobeNewsWire

Bavarian Nordic Publishes Annual Report 2023

COPENHAGEN, Denmark, March 6, 2024 – Bavarian Nordic A/S (OMX: BAVA) today published its Annual Report for 2023. The consolidated, audited results were in line with the preliminary results, announced ...

6 weeks ago - GlobeNewsWire

Bavarian Nordic's Chikungunya Vaccine Candidate Granted Accelerated Assessment by European Medicines Agency

COPENHAGEN, Denmark, February 23, 2024 – Bavarian Nordic A/S (OMX: BAVA) (“the Company”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...

7 weeks ago - GlobeNewsWire

Bavarian Nordic delivered record financial results in 2023

COPENHAGEN, Denmark, February 21, 2024 – Bavarian Nordic A/S (OMX: BAVA) today reports preliminary, unaudited financial results for 2023 and financial guidance for 2024. Furthermore, the Company provi...

2 months ago - GlobeNewsWire

New Incentive Program Established for Members of Executive Management and Selected Employees in Bavarian Nordic

COPENHAGEN, Denmark, December 13, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Board of Directors has decided to establish a new long-term incentive program for Executive Management...

4 months ago - GlobeNewsWire

Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise

COPENHAGEN, Denmark, November 30, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company's share capital has been increased by nominally DKK 1,692,300 as a consequence of employees' e...

4 months ago - GlobeNewsWire

Bavarian Nordic to hold Capital Markets Days in February 2024

COPENHAGEN, Denmark, November 22, 2023 – Bavarian Nordic A/S (OMX: BAVA) will hold a series of capital markets days in February 2024 for investors and analysts across Europe and the U.S.

5 months ago - GlobeNewsWire

Bavarian Nordic Announces Interim Results for the First Nine Months of 2023

COPENHAGEN, Denmark, November 16, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results for the first nine months of 2023 and business progress for the third quarter of ...

5 months ago - GlobeNewsWire

US CDC panel recommends Bavarian Nordic's vaccine for adults at risk of mpox

Bavarian Nordic said on Wednesday the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) has voted in favor of recommending the routine use of ...

6 months ago - Reuters

Bavarian Nordic's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk

COPENHAGEN, Denmark, October 25, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (A...

6 months ago - GlobeNewsWire

Bavarian Nordic Awarded Another Contract to Supply Smallpox Vaccines for EU Strategic Reserve

COPENHAGEN, Denmark, September 13, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today, that it has been awarded another contract valued at more than EUR 11 million to supply its MVA-BN® smallpox v...

7 months ago - GlobeNewsWire

Bavarian Nordic Provides Update on COVID-19 Booster Vaccine Program

COPENHAGEN, Denmark, August 31, 2023 – Bavarian Nordic A/S (OMX: BAVA) today reported additional Phase 3 results and provided an update on the development program for its cVLP-based COVID-19 booster v...

8 months ago - GlobeNewsWire

Bavarian Nordic Announces First Half 2023 Results

COPENHAGEN, Denmark, August 23, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first half of 2023 and released its financial calenda...

8 months ago - GlobeNewsWire

Bavarian Nordic Reports Positive Phase 3 Topline Results for Chikungunya Virus Vaccine in Adults and Adolescents

COPENHAGEN, Denmark, August 6, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today positive topline results from a randomized, double-blind, placebo-controlled Phase 3 clinical trial ( NCT05072080 ...

9 months ago - GlobeNewsWire

Bavarian Nordic Receives USD 120 Million Contract for the Manufacturing of Smallpox and Mpox Vaccine from the U.S. Government

COPENHAGEN, Denmark, August 3, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strat...

9 months ago - GlobeNewsWire

Bavarian Nordic to discontinue RSV vaccine programme

Denmark-based Bavarian Nordic said on Saturday it was discontinuing its respiratory syncytial virus (RSV) vaccine programme as its Phase 3 clinical trial did not meet all the primary goals of preventi...

9 months ago - Reuters

Bavarian Nordic Provides Update on RSV Vaccine Program

COPENHAGEN, Denmark, July 22, 2023 – Bavarian Nordic A/S (OMX: BAVA) today announced that its Phase 3 clinical trial of MVA-BN® RSV, a respiratory syncytial virus (RSV) vaccine candidate for adults ≥6...

9 months ago - GlobeNewsWire

Bavarian Nordic Reports Phase 3 Topline Results for its COVID-19 Booster Vaccine Candidate

COPENHAGEN, Denmark, June 27, 2023 – Bavarian Nordic A/S (OMX: BAVA) today reported topline results from a Phase 3 non-inferiority clinical trial of ABNCoV2, a VLP-based, non-adjuvanted COVID-19 boost...

10 months ago - GlobeNewsWire

Bavarian Nordic to Supply Smallpox Vaccines for EU Strategic Reserve

COPENHAGEN, Denmark, June 23, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today, that it has been awarded a contract valued at EUR 10 million to supply its smallpox vaccine to rescEU, a strategic...

10 months ago - GlobeNewsWire

Bavarian Nordic Reports Data from a Phase 3 Clinical Trial of its VLP-Based Chikungunya Virus Vaccine in Adults ≥65 Years of Age

COPENHAGEN, Denmark, June 20, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today the initial safety and immunogenicity results from a randomized, double-blind, placebo-controlled Phase 3 clinical ...

10 months ago - GlobeNewsWire

Bavarian Nordic Reports 12-Month Durability Data from a Phase 2 Clinical Trial of its COVID-19 Vaccine Candidate

COPENHAGEN, Denmark, June 16, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today the results of a 12-month follow-up analysis from a subset of subjects enrolled in a Phase 2 clinical trial of ABNC...

10 months ago - GlobeNewsWire